Table 3 PRDM5 methylation and expression and other molecular features of serrated and conventional polyp subgroups
From: Methylation and expression of the tumour suppressor, PRDM5, in colorectal cancer and polyp subgroups
| Â | Serrated Polyps | Conventional Adenomas | P value | |||
|---|---|---|---|---|---|---|
| Â | MVHP | SSA | TSA | TVA | TA | Serrated vs conventional |
N | 19 | 20 | 20 | 20 | 20 | - |
PRDM5 Methylation | 2 (11%) | 2 (10%) | 2 (10%) | 0 | 0 | 0.08 |
PRDM5 Average | 3.4 | 2.2 | 3.6 | 1.1 | 0.4 | 0.01 |
PMR score | ||||||
PRDM5 IHC | 5 (26%) | 12 (60%) | 12 (60%) | 12 (60%) | 11 (55%) | 0.5 |
Negative Expression | ||||||
BRAF mutation | 18 (95%) | 17 (85%) | 13 (65%) | 0 | 0 | <0.0001 |
KRAS mutation | 0 | 1 (5%) | 4 (20%) | 3 (15%) | 1 (5%) | 1.0 |
CIMP High | 2 (11%) | 12 (60%) | 9 (45%) | 0 | 0 | <0.0001 |
Nuclear Beta-Catenin | 0 | 0 | 3 (15%) | 17 (85%) | 9 (45%) | <0.0001 |